Drug
Sodium zirconium cyclosilicate clinical trials
Also written Lokelma and ZS.
Keep track of what changes. Save the sodium zirconium cyclosilicate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2021 (9)
| Year | Studies |
|---|---|
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 9 |
| 2022 | 4 |
| 2024 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 11
AstraZeneca (15) · ZS Pharma, Inc. (3) · Fundación para la Investigación del Hospital Clínico de Valencia (2) · Michael Fu (1) · St George's, University of London (1) · Alexandria University (1) · Guangdong Provincial People's Hospital (1) · Qianfoshan Hospital (1)
Often tested with
Tested in the same studies.
Polystyrene sulfonic acid (2) · Tacrolimus (1) · Cyclosporine (1) · Polyethylene glycol 3350 (1) · Patiromer (1)
Studies
Open first, then newest update. How each study uses sodium zirconium cyclosilicate is read from its arms, and is right about nine times in ten.
Testing it · 29
- Keeping RAASi Treatment With Optimal Potassium ControlRecruitingPhase 3Fundación para la Investigación del Hospital Clínico de ValenciaNCT06578533Written as Sodium Zirconium Cyclosilicate
- A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly PatientsRecruitingPhase 3Fundación para la Investigación del Hospital Clínico de ValenciaNCT06578078Written as Sodium Zirconium Cyclosilicate
- Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4RecruitingPhase 4Leiden University Medical CenterNCT06365684Written as Sodium zirconium cyclosilicate
- The Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis PatientsNot yet recruitingPhase 4Qianfoshan HospitalNCT06736184Written as Sodium Zirconium Cyclosilicate (SZC)
- Lokelma for RAAS Maximisation in CKD & Heart Failure.CompletedPhase 3St George's, University of LondonNCT05004363Written as Lokelma Oral Product
- Comparison of Potassium Binders in the ERTerminatedPhase 4University of California, IrvineNCT04585542Written as Sodium zirconium cyclosilicate
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of HyperkalaemiaTerminatedPhase 3AstraZenecaNCT05056727Written as Sodium Zirconium Cyclosilicate (SZC)
- Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge StudyCompletedPhase 4AstraZenecaNCT05347693Written as Sodium Zirconium Cyclosilicate (SZC)
- Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving SpironolactoneCompletedPhase 4AstraZenecaNCT04676646Written as Sodium zirconium cyclosilicate
- OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart FailureActive, not recruitingPhase 2Michael FuNCT04789239Written as Sodium zirconium cyclosilicate
- Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)TerminatedPhase 3AstraZenecaNCT04847232Written as Sodium Zirconium Cyclosilicate (SZC)
- The ORTIZ Study: Optimising RASi Therapy With SZCTerminatedPhase 2Barts & The London NHS TrustNCT04983979Written as Sodium Zirconium Cyclosilicate
- A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.CompletedPhase 3AstraZenecaNCT03528681Written as Sodium Zirconium Cyclosilicate 5g
- SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis PatientsCompletedNot applicableAlexandria UniversityNCT06029179Written as sodium zirconium cyclosilicate (SZC)
- Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy SubjectsCompletedPhase 1AstraZenecaNCT04788641Written as Sodium Zirconium Cyclosilicate
- Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney DiseaseTerminatedPhase 3AstraZenecaNCT04727528Written as Sodium zirconium cyclosilicate
- Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese SubjectsCompletedPhase 3AstraZenecaNCT04217590Written as Sodium Zirconium Cyclosilicate
- Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With HyperkalaemiaTerminatedPhase 4AstraZenecaNCT04997161Written as Sodium Zirconium Cyclosilicate (SZC)
- Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After ParathyroidectomyCompletedPhase 3Guangdong Provincial People's HospitalNCT05382988Written as Sodium zirconium cyclosilicate
- Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart FailureTerminatedPhase 2AstraZenecaNCT03532009Written as Sodium Zirconium Cyclosilicate
See all 29 studies that test sodium zirconium cyclosilicate →
Codes
What other systems call sodium zirconium cyclosilicate · ClinicalTrials.gg INT000213
- MeSH (NLM) C000597310sodium zirconium cyclosilicateConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) D652ZWF066SODIUM ZIRCONIUM CYCLOSILICATEConfirmed FDA, NLM
- RxNorm 2047628One source FDA
- NCI Thesaurus C152381Sodium Zirconium CyclosilicateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000597310 | sodium zirconium cyclosilicate | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D652ZWF066 | SODIUM ZIRCONIUM CYCLOSILICATE | Confirmed FDA, NLM |
| RxNorm | 2047628 | — | One source FDA |
| NCI Thesaurus | C152381 | Sodium Zirconium Cyclosilicate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.